BRIEF

on MEDIAN TECHNOLOGIES (EPA:ALMDT)

Median Technologies strengthens its position with pharmaceutical giants

Stock price chart of MEDIAN TECHNOLOGIES (EPA:ALMDT) showing fluctuations.

On May 21, 2024, Median Technologies, specialized in imaging services for clinical trials in oncology, announced its partnership with a new pharmaceutical laboratory member of the Top 3 worldwide.

With this new agreement, Median becomes the preferred supplier of two of the three largest global laboratories, dominant in terms of revenue in oncology. The contract concerns late-phase clinical trials requiring centralized image reading.

This partnership confirms Median's ability to offer high quality services in the clinical trials sector, particularly in the United States. Using artificial intelligence-based technologies, the company optimizes the operations of its pharmaceutical clients and improves their growth prospects.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all MEDIAN TECHNOLOGIES news